We determined the safety and efficacy of deoxycholate-amphotericin B (d-AmB) mixed with Intralipid (IL) as the initial treatment of AIDS-associated cryptococcal meningitis in a phase II, multicentre, non-comparative open study, assessing two dosages of ILd-AmB: 1 mg/kg (group A, n = 9) and 1.5 mg/kg (group B, n = 6). Patients were treated daily for 2 weeks, then three times weekly for 4 weeks. The ILd-AmB dosage was decreased due to toxicity in three patients in each group. Serum creatinine increased significantly on day 14 in group A and on day 7 in group B. Nephrotoxicity, (serum creatinine level >165umol/L) was noted in two and five patients in groups A and B, respectively. Nine adverse haematological events were noted (seven cases of anaemia requiring transfusion, and two cases of neutropenia <750/mm). Two patients had an increase in serum alkaline phosphatase. In each cohort, 15% of the infusions were associated with fever and/or chills. Successful outcome was obtained in half of the patients. We conclude that, in AIDS patients with cryptococcosis, tolerance to ILd-AmB was acceptable when the daily dosage did not exceed 1 mg/kg, but the higher 1.5 mg/kg daily dosage was associated with an unacceptable rate of nephrotoxicity. Neither of these relatively high daily dosages of ILd-AmB achieved an improved rate of successful outcomes compared with lower daily dosages of conventional d-AmB in glucose.
Introduction
Cryptococcosis occurs most frequently in immunocompromised hosts, especially patients with AIDS. Between 15-30% of AIDS patients with cryptococcal meningitis die during induction therapy, and most deaths occur within the first few weeks of illness (Chuck & Sande, 1989; Saag et al., 1992) . Fluconazole has been shown to be the treatment of choice for maintenance therapy , but the optimal initial therapy is still controversial. In contrast to what is observed in immunocompetent patients, complete cure is very unlikely in AIDS patients and the primary objectives are control of the infection, decrease in early mortality, prevention of relapse and maintenance of quality of life. The current trend is to use an aggressive initial regimen with amphotericin B at a high dosage (0.7-1 mg/kg/day) (Armstrong, 1993; Dismukes, 1993; Powderly, 1993; Van der Horst et al., 1995) , with or without flucytosine.
The conventional formulation of amphotericin B, deoxycholate-amphotericin B (d-AmB) dissolved in 5% dextrose, is associated with significant infusion-related morbidity (fever, chills) and nephrotoxicity. Different formulations of amphotericin B (liposomal amphotericin B, amphotericin B-lipid complexes and amphotericin B colloidal dispersion), primarily designed to reduce toxicity, have entered clinical trials. Data on their usefulness in AIDS patients with cryptococcosis remain limited (Graybill et al., 1991; Cokeref al., 1993) , and they have not been compared with the conventional amphotericin B formulation in large prospective trials. Furthermore, the high cost of these lipid-associated amphotericin B formulations precludes large-scale use.
Intralipid is a commercially available lipid emulsion for parenteral nutrition. In neutropenic patients, it has been shown that d-AmB emulsified in 20% Intralipid (ILd-AmB) was less often responsible for fever, chills and decreased creatinine clearance than d-AmB dissolved in dextrose (Chavanet et al., 1992; Moreau et al., 1992; Caillot et al., 1994) , whereas it remained effective in the treatment of systemic candidiasis (Caillot et al., 1993) . Experimentally, we have shown that ILd-AmB was less toxic than and as efficient as d-AmB in dextrose in mice with experimental cryptococcosis, and that Intralipid enhanced the therapeutic activity of the drug by allowing larger doses of d-AmB to be infused (Joly et al., 1994) .
In the present study, we determined the safety and evaluated the efficacy of ILd-AmB in the treatment of cryptococcal meningitis in AIDS patients.
Patients and methods

Study population
The criteria for enrolment included HIV infection documented by a positive confirmatory test for anti-HIV antibodies, age ^ 18 years and a positive cerebrospinal fluid (CSF) culture for Cryptococcus neoformans. Patients could be enrolled on the basis of preliminary evidence of acute cryptococcal meningitis, including a positive CSF test for cryptococcal antigen or a positive CSF India ink preparation. However, the CSF culture had to be positive for the patient to be assessable. Cryptococcosis was either an initial episode or a relapse following successful treatment. Patients were excluded for enrollment if they had received more than 1 mg/kg of iv amphotericin B within 1 week before entry, were pregnant, comatose, had a Karnofsky score <;20, abnormal liver function tests (more than five times the upper limit of normal values), a creatinine clearance rate of less than 30 mL/min, or marked haematological abnormalities (haemoglobin <8g/dL, absolute neutrophil count <750/mm 3 or platelets <75,000/ mm 3 ). Treatment with other systemic antifungal drugs was not allowed during the study. The study protocol was reviewed and approved by the Bichat-Claude Bernard Hospital Ethics Committee, and all enrolled patients gave informed consent.
Preparation of the ILd-AmB formulation
All patients were treated with the same batch of parenteral d-AmB (Fungizone) obtained from Squibb (Neuilly sur Seine, France). The 20% Intralipid emulsion was obtained from Kabi Pharmacia (Saint Quentin en Yvelines, France). An initial ILd-AmB preparation was obtained by adding 10 mL of 20% Intralipid directly to the vial containing 50 mg of Fungizone. The vial was vigorously shaken by hand until a homogenous yellow emulsion was obtained. The total amount of ILd-AmB necessary to treat the patient, according to weight and the assigned unit dose, was further diluted in 20% Intralipid to obtain a final volume of 50 mL, which was given iv over 2 h as a continuous infusion. In every case, the mixture was used immediately after preparation.
Treatment
The study was a cooperative multicentre investigation. Patients were enrolled at different centres and treated according to a single protocol. They started therapy between July 1992 and October 1993. Treatment was initiated after a test dose of 1 mg ILd-AmB had been infused over 30 min without side effects. ILd-AmB was given daily for 14 days, then three times weekly for 28 days. Two amphotericin B dosages were studied: 1 mg/kg (nine patients: group A) and 1.5mg/kg (six patients: group B). The study of the 1.5 mg/kg dosage was initiated after results obtained in patients treated with 1 mg/kg had been evaluated by an independent committee. The daily amphotericin B dosage was reduced when serum creatinine concentrations exceeded 165/imol/L, and treatment was temporarily withdrawn if these exceeded 330 /imol/L. The AIDS Clinical Trial Group (ACTG) grading system was used to assess extrarenal side-effects requiring dosage reduction or discontinuation of treatment. A grade 3 extrarenal toxicity led to temporary discontinuation of treatment until biological values returned to normal or grade 1 toxicity. A grade 4 toxicity or recurrence of grade 3 toxicity led to interruption of the treatment. In the case of clinical failure, the decision to change antifungal therapy before day 42 was left to the discretion of the treating physician in agreement with the principal investigator; the antifungal therapy after day 42 was chosen by the treating physician.
Evaluation
Following baseline assessment, patients were evaluated weekly. Immediate toxicity (fever, chills, rash, nausea, abnormal blood pressure) was monitored during each infusion and for 2 h afterwards. Antipyretics were administered when necessary. Response to therapy was assesed clinically and mycologically. A clinical cure was defined as complete resolution of symptoms; clinical improvement as the resolution of some but not all clinical symptoms; clinical failure as no change or emergence of new clinical features that were not related to toxicity or to another opportunistic infection. Lumbar punctures were performed weekly. Mycological success was defined as two consecutive negative cultures of CSF samples obtained at least one week apart; mycological failure was defined as CSF cultures remaining positive or only one negative CSF culture by the end of the 6 week treatment period.
Statistical analysis
In each group, toxicity was assessed by comparing biological values measured during therapy with baseline values (day 0) using the paired Student's / test; P < 0.05 was considered significant. 
Patient characteristics
Patient characteristics are summarized in Table I . Three patients suffered relapses of previous cryptococcal meningitis and were receiving maintenance therapy with a triazole at the time of inclusion. All patients at entry had a serum creatinine concentration lower than the upper limit of the normal value (ULN). One patient in group B could not be evaluated for efficacy because of a negative baseline CSF culture; however, this patient was treated until culture results were available and was thus included in the toxicity analysis.
Presenting clinical features and CSF characteristics are summarized in Table II . Thirteen out of 14 patients had positive India ink preparations. In eight patients, CSF protein and glucose concentrations and leukocyte counts were normal, and Llpld-araphotericln B in cryptococcosls 121 "Group A includes only eight patients because of one early death on day 5 precluding the evaluation of biologic toxicity.
'Group B comprises all six patients who received this regimen, including the patient who was subsequently excluded because of a negative baseline CSF culture.
r ULN, Upper limit of normal range.
cryptococcosis was suspected based on India ink staining and cryptococcal antigen positivity of the CSF.
Toxicity
The side-effects are summarized in Table III . Reduction of the ILd-AmB dose because of toxicity was necessary for three group A patients (one patient each for haematological toxicity, increased alkaline phosphatase level and nephrotoxicity), and for three out of the four group B patients treated for more than 7 days (for nephrotoxicity in all cases). Serum creatinine concentration (mean ± s.D.) increased from 83 ± 11 /^mol/L on day 0 to 118 ± 40 ftmo\/L on day 14 (P < 0.05) in group A, and from 92 ± 15 /imol/L on day 0 to 174 ± 42 /imol/L on day 7 (P < 0.05) in group B. Two patients in group A and five patients in group B had increases in serum creatinine above 165 /jmol/L, occurring as early as day seven in four cases in group B. Nine adverse haematological events were noted. None of these subjects received associated haematotoxic drugs. Although no grade 3 thrombocytopenia was observed, the mean thrombocyte count decreased significantly on day seven in group A (P < 0.05). Two cases of hepatic toxicity (alkaline phosphatase > 10 x ULN, with associated concomitant raised aminotransferases in one case) were observed in group A. Both patients had abnormal alkaline phosphatase baseline values (2 and 4.6 x ULN) at inclusion. Hepatic toxicity regressed after the study. In group B, too few patients remained under therapy after day seven to allow statistical analysis beyond this time.
The incidence of infusions associated with fever (defined as an increase of temperaturê 1°C) and/or chills was 15.1% in group A and 15.7% in group B. In light of the deleterious effects observed with the 1.5 mg/kg dosage, particularly nephrotoxicity, the study was closed after enrollment of the first six patients in group B, and no higher dosage of ILd-AmB was studied.
Efficacy
Results are reported in Table IV . In group A, death occurred in one patient on day five as a complication of general anaesthesia. Although the relationship between death and cryptococosis remained uncertain in this subject, he was assessed as a failure of therapy. Five patients were clinically cured or improved on day 42. All these patients had two consecutive negative CSF cultures one week apart, the first negative culture being obtained on day seven in four patients and on day 14 in the fifth. However, for three of these five patients, the cultures of CSF sampled at the end of therapy were positive (one to few colonies) despite clinical cure. Three other patients suffered clinical progression with persistent positive CSF cultures. Among them, one patient was switched to d-AmB in dextrose on day 10, and subsequently had clinical and mycological cure; one patient died on day 33, despite increasing the dosage of ILd-AmB to 1.5mg/kg on day 29. The third patient remained in the study until day 42. He developed oesophageal candidosis under therapy and also multiple low attenuation lesions on cerebral computed tomography. As of day 42, ILd-AmB was switched to d-AmB in dextrose (1 mg/kg/day), without clinical improvement. Despite the continuous antifungal therapy, repeated CSF cultures remained positive and the patient died of cryptococcosis 4 months after diagnosis.
In group B, regimen efficacy could be evaluated in only five patients, because the baseline CSF culture was negative in one subject. Two patients were cured clinically and mycologically. One patient was cured clinically, without CSF sterilization (one colony was cultured from a sample taken on day 42). One patient did not respond to therapy and died on day 26 with disseminated cryptococcosis. The last patient was switched to d-AmB in dextrose and flucytosine on day six because of clinical derioration; however, the CSF culture performed before switching was negative.
Overall, seven of the 12 patients that could be evaluated for mycological response had CSF sterilization, giving a response rate of 58%. For these successfully treated patients, the median time to a negative CSF culture was 7 days. When unassessable patients (one early death as complication of general anaesthesia, one switch to d-AmB in dextrose and flucytosine on day 6) were included in the mycological analysis as failures, the response rate declined to 50%. In all patients with favourable mycological outcome, sterilization of CSF was obtained as early as day 14.
Discussion
The treatment of cryptococcosis in AIDS patients has been extensively investigated, but the best induction therapy has not yet been clearly determined (British Society for Antimicrobial Chemotherapy Working Party, 1992). Most investigators agree that initial therapy with 0.7-1 mg/kg of amphotericin B is appropriate. However, nephrotoxicity often limits the duration of treatment , and the daily dosage is often influenced more by changes in renal function than by the response of the patient to therapy. Improved tolerance to amphotericin B is therefore needed. Encouraging results have been reported with ILd-AmB in neutropenic patients with systemic candidiasis (Caillot et al., 1993) , and in HIV patients with oral candidosis (Chavanet et al., 1992) , but no data are available in AIDS patients with cryptococcosis.
In our study, the analysis of baseline clinical manifestations was concordant with the data reported previously in AIDS patients (Coker et al., 1993; Rozenbaum & Goncalves, 1994) , and our group of patients was representative of the disease, except that alteration of mental status was not often noted, due to the exclusion of comatose patients.
We observed a low rate of fever and chills due to infusion (approximately 15%), but the decision to use antipyretics was left to the discretion of the treating physician, including preventive administration when severe manifestations had been observed during the first infusions. In other studies, performed in neutropenic patients (Moreau et al., 1992; Caillot et al., 1993; or HIV patients with oral candidosis (Chavanet et al., 1992) , the rate of fever and chills was reported between 1 and 30%. Renal tolerance to ILd-AmB was satisfactory, compared with the conventional formulation, in group A, although a significant increase in serum creatinine concentration was noted on day 14, and two of the eight patients had an increase above 1.5 x ULN. Increasing the dosage to 1.5 mg/kg led to evident nephrotoxicity, since serum creatinine concentrations became significantly elevated as early as day 7, and five of the six patients had increases above 1.5 x ULN, following a cumulative dose of ILd-AmB of less than 1.3 g. In contrast, with AmBisome at a mean daily dosage of 3 mg/kg, the maximum rise in serum creatinine concentration was 1.3 x ULN, and no change was noted following a cumulative dose of 4 g of AmBisome (Coker et al., 1993) . Although we prepared ILd-AmB in the same manner as other groups (Chavanet et al., 1992; Caillot et al., 1993 Caillot et al., , 1994 , we observed a higher rate of nephrotoxicity. This could be related to the use of a higher daily dosage, since nephrotoxicity occurred mainly in our 1.5 mg/kg treated patients, whereas in previous studies (Chavanet et al., 1992; Moreau et al., 1992; Caillot et al., 1993 Caillot et al., , 1994 , the mean daily dosage did not exceed 1.2 mg/kg. Another difference between the present study and previously reported results is the characteristics of patients studied. Most previous studies have been conducted in neutropenic patients with haematologic malignancies, who are usually monitored in intensive care units and receive large saline infusions, that could contribute to the reduced observed incidence of toxicity of d-AmB.
The present study also highlighted the potential haematological toxicity of ILd-AmB. This toxicity was not previously identified, probably because the formulation had been evaluated in subjects with pancytopenia. Haematological toxicity, particularly anaemia, has been described with conventional amphotericin B. Haematocrit decreases of more than 10 units occurred during 76% of the treatment courses . Mechanisms of anaemia have not yet been completely elucidated, and haemolysis, decreased erythropoietin production or direct toxicity against progenitor cells have been discussed (Gallis, Drew & Pickard, 1990) . Decreased white blood cell counts have been reported for patients treated with AmBisome (Coker et al., 1993) , but the cumulative dosage of amphotericin B was clearly high in this latter study. In our study, the occurrence of haematological side effects could be due to the usual toxicity of d-AmB, or to a preferential targeting of d-AmB towards bone marrow in the presence of Intralipid. Finally, a marked alteration of the results of liver function tests, mainly alkaline phosphatase, was observed in two patients. No other hepatotoxic therapy was administered simultaneously, and ILd-AmB is therefore implicated. It has to be stressed that one of these two patients had abnormal baseline hepatic function test values due to chronic hepatitis. No hepatocellular failure was noted, and these values returned to pretherapeutic levels after therapy. Hepatotoxicity is rare with conventional d-AmB (Millier, 1984) , but an increase in hepatic enzymes has also been reported with AmBisome in cryptococcosis (Coker et al., 1993) . Here again, passive targeting of the drug into the reticuloendothelial system may be responsible for these observations. Another hypothesis could be the toxicity of the emulsion as a consequence of abnormal degradation of lipids by triglyceride lipase in the presence of d-AmB.
Due to the small number of patients and the lack of a comparative group of patients treated with d-AmB in dextrose, assessment of efficacy was difficult and no firm conclusion can be drawn. We compared the observed response rate with data published on AIDS patients. The duration of therapy in our study was relatively short, but after six weeks the physician could administer the treatment of his choice, according to the response obtained. However, the maximal response rate was obtained as early as day 14. Our 50% response rate compared favourably with the CSF sterilization rates obtained with fluconazole (34%) or d-AmB in dextrose at the median daily dosage of 0.45 mg/kg (40%) . In contrast, in one study, all six patients who received amphotericin B (0.7 mg/kg/day) plus flucytosine (150 mg/kg/day) had successful outcomes after 10 weeks of therapy (Larsen, Leal & Chan, 1990) . The major Mycosis Study Group-ACTG investigation (Van der Horst et al., 1995) reported a 51 % response rate after 2 weeks of d-Amb in dextrose (0.7 mg/kg/d). Since, in the present study, the response rate did not exceed 50% in spite of a daily dosage of at least 1 mg/kg, our results imply a reduced efficacy of ILd-AmB compared with conventional d-AmB at the same dose. With AmBisome (3 mg/kg/d), the response rate measured after at least 42 days of daily treatment in a non-comparative study was 67%, with a median time to a negative culture of 11 days (Coker et al., 1993) . The patients from the present study had some poor risk factors, including prior cryptococcal meningitis, high cryptococcal antigen titre and low level of cellular reaction in CSF. However, since only two of these had abnormal mental status, the most important predictor of outcome (Chuck & Sande, 1989; Saag et al., 1992) , the value of ILd-AmB in patients with altered consciousness remains unknown. Finally, in three patients with two consecutive early negative CSF cultures one week apart, we observed a positive culture at the end of therapy, but without clinical relapse. From day 14, treatment was administered every other day, and a late positive culture could be due to a premature reduction in the total weekly dosage.
In conclusion, this trial has shown that tolerance of ILd-AmB, when given at a dosage of 1 mg/kg/d, was acceptable in AIDS patients with cryptococcosis. However, reduction of d-AmB nephrotoxicity by Intralipid was not clearly established in this group of subjects, and increasing the daily dosage of ILd-AmB to 1.5 mg/kg led to an unacceptable rate of early renal toxicity. Preliminary evidence that ILd-AmB remained effective was also obtained, although the high daily dosage of ILd-AmB was not associated with increased efficacy; this implies that ILd-AmB could be less effective than d-AmB in dextrose, when both formulations are given at the same dosage. Only comparative assessment of both toxicity and efficacy of conventional d-AmB and ILd-AmB in cryptococcal meningitis will determine more precisely whether or not Intralipid improves the therapeutic index of d-AmB.
